drug development

By Dave Muoio July 10, 2019
Clover Health, an Alphabet-backed insurtech startup serving the Medicare Advantage market, announced this morning the launch of a new subsidiary unit that will be focused on using data from its members to drive drug development. Much like its parent company uses machine learning and artificial intelligence to generate predictive health insights for its member population, Clover Therapeutics will...
By Nathan Eddy July 9, 2019
Cloud-based computing could offer major benefits to pharmaceutical companies in the area of drug development as they grapple with rising costs and avalanches of data that need to be collected, analyzed and shared. In particular, the technology could help streamline operations and develop business cases as to whether a drug is likely to be needed — or financially viable. “If you’ve got big pots of...
By Laura Lovett July 1, 2019
It would be hard to discuss healthcare trends without talking about what this means for the behemoth pharma industry. Recently, new kid on the block digital health has started to turn heads in across this well-established sector with its potential for improving R&D, tracking real-world evidence and even creating a new type of medicine with digital therapeutics.  While digital promises the...
By Jonah Comstock March 29, 2019
At MEDinIsrael 2019 this week, a conference in Tel Aviv sponsored by the Israeli Export Institute, Dr. Lena Granovsky, director of analytics and big data at Teva Pharmaceuticals, spoke on and off stage about the work the top Israeli pharma company has been doing in digital health. These topics included the company's recently FDA-cleared smart inhaler ProAir Digihaler, as well as more broad...
By Dave Muoio June 12, 2018
Medidata, a New York City-based company that offers cloud storage and data analytics services for clinical trials, announced today that it has acquired Shyft Analytics, maker of a cloud data analytics platform specifically designed for the pharma and biotech industries. The transaction valued Shyft at $195 million, inclusive of Medidata’s prior 6 percent ownership in the analytics platform, to be...
By Jonah Comstock April 20, 2018
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million. “We are very pleased with the response to the fundraising," Ken Mulvany,...